Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$144.95 - $152.29 $23,626 - $24,823
-163 Reduced 0.01%
1,525,202 $231 Million
Q2 2022

Aug 15, 2022

SELL
$83.14 - $145.99 $96.2 Million - $169 Million
-1,157,551 Reduced 43.15%
1,525,365 $222 Million
Q1 2022

May 16, 2022

SELL
$110.08 - $142.92 $256 Million - $332 Million
-2,322,910 Reduced 46.4%
2,682,916 $318 Million
Q4 2021

Feb 14, 2022

SELL
$99.73 - $148.48 $35.8 Million - $53.3 Million
-359,239 Reduced 6.7%
5,005,826 $690 Million
Q3 2021

Nov 15, 2021

SELL
$98.85 - $138.91 $27.3 Million - $38.3 Million
-275,997 Reduced 4.89%
5,365,065 $745 Million
Q2 2021

Aug 16, 2021

BUY
$65.78 - $105.02 $4.13 Million - $6.6 Million
62,830 Added 1.13%
5,641,062 $548 Million
Q1 2021

May 14, 2021

BUY
$64.07 - $91.75 $15.8 Million - $22.7 Million
247,254 Added 4.64%
5,578,232 $381 Million
Q4 2020

Feb 12, 2021

SELL
$65.07 - $98.24 $27.1 Million - $40.9 Million
-416,207 Reduced 7.24%
5,330,978 $457 Million
Q3 2020

Nov 13, 2020

SELL
$59.04 - $77.95 $15.5 Million - $20.5 Million
-262,830 Reduced 4.37%
5,747,185 $374 Million
Q2 2020

Aug 14, 2020

BUY
$29.01 - $74.23 $182,182 - $466,164
6,280 Added 0.1%
6,010,015 $439 Million
Q1 2020

May 15, 2020

BUY
$27.51 - $57.29 $84.8 Million - $177 Million
3,082,031 Added 105.49%
6,003,735 $204 Million
Q4 2019

Feb 18, 2020

BUY
$40.86 - $57.65 $61.6 Million - $87 Million
1,508,804 Added 106.79%
2,921,704 $159 Million
Q3 2019

Nov 14, 2019

BUY
$37.38 - $49.47 $747,600 - $989,400
20,000 Added 1.44%
1,412,900 $58.9 Million
Q2 2019

Aug 14, 2019

BUY
$39.79 - $67.01 $55.4 Million - $93.3 Million
1,392,900 New
1,392,900 $61 Million

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $2.8B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Capital International Investors Portfolio

Follow Capital International Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.